{
    "root": "29139c6f-70e7-44a8-8b6f-fff7a394ac03",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "MYXREDLIN",
    "value": "20250307",
    "ingredients": [
        {
            "name": "INSULIN HUMAN",
            "code": "1Y17CTI5SR"
        },
        {
            "name": "SODIUM PHOSPHATE, DIBASIC, ANHYDROUS",
            "code": "22ADO53M6F"
        },
        {
            "name": "SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE",
            "code": "593YOG76RN"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        }
    ],
    "indications": "myxredlin indicated improve glycemic control adults pediatric patients diabetes mellitus .",
    "contraindications": "• inspect myxredlin visually . appear clear colorless . myxredlin particulate matter coloration seen . ( 2.1 ) • administer myxredlin intravenously medical supervision close monitoring blood glucose potassium levels . ( 2.1 ) • add supplementary medication additives . ( 2.1 ) • series connections . ( 2.1 ) • shake freeze . discard unused portion . ( 2.1 ) • individualize dose based metabolic needs , blood glucose monitoring results , glycemic control goal . ( 2.2 ) • adjustments may needed changes nutrition , renal , hepatic function acute illness . ( 2.2 )",
    "warningsAndPrecautions": "myxredlin ( insulin human ) 0.9 % sodium chloride injection contains 100 units/100 ml ( 1 unit/ml ) insulin human 0.9 % sodium chloride clear , colorless solution available : 100 ml single-dose galaxy container , package 12 , ndc 0338-0126-12",
    "adverseReactions": "myxredlin contraindicated : •during episodes hypoglycemia •in patients hypersensitivity insulin human excipients myxredlin",
    "indications_original": "MYXREDLIN is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.",
    "contraindications_original": "• Inspect MYXREDLIN visually before use.  It should appear clear and colorless.  Do not use MYXREDLIN if particulate matter or coloration is seen. ( 2.1 ) • Administer MYXREDLIN intravenously ONLY under medical supervision with close monitoring of blood glucose and potassium levels. ( 2.1 ) • Do not add supplementary medication or additives. ( 2.1 ) • Do not use in series connections. ( 2.1 ) • Do not shake or freeze.  Discard unused portion. ( 2.1 ) • Individualize dose based on metabolic needs, blood glucose monitoring results, and glycemic control goal. ( 2.2 ) • Dosage adjustments may be needed with changes in nutrition, renal, or hepatic function or during acute illness. ( 2.2 )",
    "warningsAndPrecautions_original": "MYXREDLIN (insulin human) in 0.9% sodium chloride injection contains 100 units/100 mL (1 unit/mL) of insulin human in 0.9% sodium chloride and is a clear, colorless solution available as:\n                        \n                           \n                               100 mL single-dose GALAXY container, package of 12, NDC 0338-0126-12",
    "adverseReactions_original": "MYXREDLIN is contraindicated:\n                  \n                     \n                        •During episodes of hypoglycemia\n                     \n                        •In patients with hypersensitivity to insulin human or any of the excipients in MYXREDLIN"
}